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Abstract Giant pituitary adenomas (GPAs), defined as ≥40 mm in one extension, present a 
challenging subgroup of pituitary adenomas in terms of radical tumor removal and 
complication rates. The potential impact of intraoperative magnetic resonance imaging 
(iMRI) is investigated in a consecutive series and the results compared to the literature. From 
November 2004 until February 2005, six (five male) patients were operated for GPAs via an 
iMRI-guided transsphenoidal approach in the PoleStar™ N20. Clinical, endocrinological and 
neuroradiological outcomes (at three months and yearly postoperative over four years) were 
assessed. Mean age was 46 years (range, 34-60). All patients presented with preoperative 
visual field defects, five with pituitary failure. Five adenomas were clinically non functioning, 
one was producing GH and TSH. Preoperative imaging showed invasion of the cavernous 
sinus in all and extension to the interventricular foramen in two patients (one with occlusive 
hydrocephalus). Resection was total in four and subtotal (small cavernous sinus remnants) in 
two patients, leading to transsphenoidal reoperation in one patient. Visual acuity and fields 
improved in all six patients. The patient with occlusive hydrocephalus developed a 
postoperative CSF leak (subsequently revised), two patients developed temporary, one 
permanent central DI, and one of them transient hyponatremia. Compared to the preoperative 
situation, endocrine status in the long-term follow-up (mean, 25 months) remained unchanged 
in four and worsened in two. Two patients were considered not to require hormone 
replacement therapy. IMRI supports transsphenoidal resections of GPAs because residual 
adenoma and related risk structures are easily detected and localized intraoperatively, 
extending the restricted visual access of the microscope beyond mere surface anatomy to a 
three-dimensional view. More radical removal of adenomas in a single surgical session 
combined with low complication rates are accomplished. This may add to a favorable clinical 
and endocrinological outcome in GPAs. 
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Introduction 
Giant pituitary adenomas (GPAs), which comprise a subgroup of pituitary adenomas (PAs), 
are inconsistently defined when it comes to size. Hardy’s classification groups PAs into four 
types, according to qualitative extensions [11,14]. Other authors define GPAs as tumors ≥30 
mm in diameter [1, 8], as ≥40 mm in diameter [9, 10, 19], or as tumors extending more than 
40 mm from the midpoint of the jugum sphenoidale or to within 6 mm of the interventricular 
foramen [7, 12, 18]. Patients with GPAs compared to patients with non-GPAs [8] more 
frequently present clinically with visual symptoms and headaches than hormonal disturbances 
[1, 8, 9, 12, 14]. Most GPAs are non-secreting, followed by growth hormone (GH) secretion 
and prolactinomas [1, 8, 10, 12, 14]. Radiologically, these tumors show more aggressive 
behavior with cavernous sinus (CS), skull base, and paranasal sinus invasion. Invasion or 
infiltration is not confined to a selected adenoma size or diameter and varies according to 
literature from 9 to 40%, but is more prevalent with larger tumors [8, 16]. Additionally, GPAs 
can cause occlusive hydrocephalus by impairment of cerebrospinal fluid (CSF) drainage [12]. 
Gross tumor resection thus presents a challenge to the pituitary surgeon. Numerous strategies 
(transsphenoidal, transcranial, radiotherapy, or a combination of these) have been proposed 
[1, 14, 15], including insertion of a lumbar subarachnoid catheter for saline infusion to deliver 
the suprasellar tumor into the operative field by increasing intracranial pressure [20]. 
Especially CS infiltration often makes total resection demanding or impossible. Between 
27.9% and 40% of tumors are excised totally according to several reports [1, 8, 9], and 
surgery can improve the primary symptom of the patient, diminished vision, in 65% to 90% 
[1, 9]. 
The most frequent postoperative complications include transient diabetes insipidus (DI) in 
3.7% to 18.8% and CSF leak with meningitis in 7.4% to 14.6% [8, 9]. In one study, these 
complications were not significantly more frequent than in non-giant PAs [8]. Permanent DI 
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or panhypopituitarism, third nerve palsy, and hemiparesis have been reported, as well as death 
from massive bleeding in 2.2% to 4.2% [8, 9]. 
Intraoperative magnetic resonance imaging (iMRI) has been used in the operating room for 
over a decade. As far as PAs are concerned, this imaging technique has led to a more radical 
one-stage resection of these tumors and to a decrease of perioperative morbidity and mortality 
[3, 5, 6, 13, 17], especially in macroadenomas with suprasellar extension [4]. 
We report our experience with the use of the iMRI in transsphenoidal surgery for GPAs, 
investigating the impact of this imaging modality on the amount of resection and 
complication rates, including long-term clinical, ophthalmological, endocrinological and 
neuroradiological follow-up.
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Patients and methods 
Patients with pituitary tumors ≥40 mm in one extension, who were operated in the PoleStar™ 
N20 (0.15 Tesla, Medtronic Navigation, Louisville, CO, USA) at the Department of 
Neurosurgery of the University Hospital of Zurich, Switzerland, between November 2004 and 
February 2005, were included in the study. This sample represents a cluster of such patients 
during that time. 
 
Preoperative assessment 
Preoperative computed tomography (CT) and MRI scans of the sellar region were performed 
to determine bony structures as well as tumor configuration and localization of the normal 
gland and pituitary stalk. All patients had an endocrinological investigation for pituitary 
function as well as ophthalmological exams. 
In all patients an iMRI-guided endonaso-transsphenoidal approach was used. All operations 
were performed by the senior author (RLB). 
 
Surgical technique 
The patient is placed in a supine position with the head slightly reclined and fixed in an MRI-
compatible head holder. The radio frequency coil is attached around the patient’s head. To 
optimize imaging field and quality, the center of the two adjustable magnets must be brought 
at a level close to the center of the adenoma. In most patients, a bandage is applied over the 
shoulders with careful traction in a cranio-caudal direction to reach the most basal structures 
(sphenoid sinus and clivus). The magnet’s position is tested by a 24 seconds’ scan with 8 mm-
slice thickness and T2-like specifications (e-steady sequence). The three-dimensional 
reconstruction allows immediate corrections of the magnet’s position if necessary. Then a 
seven-minute 4 mm-slice gadolinium-enhanced T1-weighted scan, which serves as baseline 
for neuronavigation, is performed. A self-retaining endonasal speculum is inserted typically in 
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the contralateral nostril or in the nostril that corresponds to the more spacious intrasphenoidal 
sinus, and its anterior wall is displayed under the operating microscope. The nasal mucosa is 
incised on the sphenoid crest with a disk knife in an inverted T-shaped fashion, and the 
anterior wall of the sphenoid sinus is removed with punches or a chisel, depending on the 
thickness of the bone. The intrasphenoidal mucosa and septum are removed with rongeur 
forceps until the anterior wall of the sella turcica to its lateral borders is displayed. This wall 
is then opened by a chisel, and the dura is incised in an x-shaped fashion with a bayonet-
handled scalpel. Using tumor grasping forceps, a suctioning device, and curettes of different 
sizes and shapes, the tumor is debulked in a stepwise fashion. Progress is verified by serial 3.5 
minute, 4 mm-slice thickness gadolinium-enhanced T1-weighted scans. Before a scan, a bone 
wax ball covered by a piece of a rubber glove is inserted in the region of the sella. This ball, 
which packs the region acting as a hemostatic by local compression, is visualized as an easily 
detectable signal-void on MRI scans and facilitates the interpretation of the iMRI images. 
Blood appears homogeneously hyperintense, whereas residual adenoma has a lower and more 
heterogeneous signal intensity. After tumor removal, the sella turcica and sphenoid sinus are 
packed with abdominal fat, covered with preserved bone fragments and sealed by tissue 
adhesive if necessary (DuraSeal™, Confluent Surgical, Waltham, MA, USA). No nasal 
packing is used routinely. 
 
Postoperative follow-up 
On the first postoperative day, a CT scan of the sellar region was performed routinely for 
detection of postoperative complications. In the days following the operation, electrolytes and 
fluid balance were monitored twice a day (including daily weight) to detect DI or syndrome 
of inappropriate antidiuretic hormone (SIADH) secretion. The patients were asked to report 
any post-nasal drip (suggestive of CSF leak). Postoperative neuro-ophthalmologic exams 
were performed before the patients left the hospital. 
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Endocrinological follow-ups usually started at one month after discharge. Clinical, 
endocrinological, and neuroradiological outcomes were assessed three months postoperative 
and continued in yearly intervals. Resection was assessed as complete if imaging and 
endocrinological studies were inconspicuous in this regard, i.e. no residual tumor visible on 
MRI scans and, in active adenomas, no pituitary hormone hypersecretion detectable.
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Results 
In the four months’ period, six patients (five men and one woman) were included in the study. 
Age ranged from 34 to 60 years (mean, 46 years). 
 
Preoperative findings (Table 1, Fig. 1) 
Visual disturbances were the leading symptom (100%) of the patients with GPAs. Fatigue 
was a complaint in two patients. Two male patients complained of sexual dysfunction. One 
patient presented with acromegaly. In one patient with sudden onset of extreme headaches 
and presumed subarachnoid hemorrhage CT scan revealed pituitary hemorrhage in a sellar 
tumor. One patient showed memory deficits, urinary incontinence and gait ataxia as primary 
symptoms, which led to cerebral imaging and identification of a large sellar mass with 
obstructive hydrocephalus. 
Examination on admittance showed visual field defects in all patients: two had bitemporal 
hemianopia, three unilateral hemianopia, and one had bitemporal quadrantanopia. 
Preoperative endocrinological testing revealed a normal hormonal status in one patient and 
multiple hormonal insufficiencies in five patients (83%): all of them had gonadotropin (GT) 
deficiency (hypogonadism, with low GTs in the postmenopausal female and low testosterone 
in the four male patients), three had thyroid stimulating hormone (TSH) deficiency (central 
hypothyroidism, low fT4), and four adrenocorticotropin hormone (ACTH) deficiency 
(secondary adrenal failure, low cortisol); in one patient with insufficiency of the pituitary-
adrenal axis but without central hypothyroidism and GH deficiency, a combined 
hyperthyroidism and excess of GH were found. The remaining five adenomas were clinically 
non functioning adenomas (NFAs). 
Preoperative imaging studies revealed invasion of the cavernous sinus in all and extension to 
the interventricular foramen in two patients, resulting in the aforementioned occlusive 
hydrocephalus in one patient. 
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Intraoperative findings 
During resection of the adenoma between two and six MR scans were performed; typically 
3.5-7 minutes, 4 mm-slice thickness gadolinium-enhanced T1-weighted scans. This led to a 
summarized scanning time of approximately 14 to 28 minutes. In all but one patient 
intraoperative scans revealed residual tumor. Surgery was continued until no residual 
adenoma was visible on the MR scans (Fig. 2). Intraoperative debulking of the intrasellar part 
of the adenoma additionally revealed the pituitary stalk indicating the localization of 
compressed gland (pituitary stalk sign). Total surgery time, including intraoperative imaging 
ranged between 2 and 4 hours (mean 2.5 hours). 
 
Postoperative findings (Table 2, Fig. 3) 
All patients underwent iMRI-guided endonaso-transsphenoidal tumor extirpation. The 
immunohistochemical profiles of the non functioning adenomas were: luteinizing hormone 
(LH) and human chorionic gonadotropin (hCG) in three each, and ACTH in one. Tumor cells 
in one patient did not stain. All patients reported markedly improved vision immediately 
following surgery. The patient with preoperative hydrocephalus developed rhinoliquorrhea 
from CSF fistula and required revision and a ventriculo-peritoneal shunt. Apart from that, 
there were no surgical complications. Postoperatively, two patients temporarily required 
desmopressin for central DI (an additional one permanently), one of them developed transient 
SIADH thereafter, which was treated with fluid restriction.  
Compared to the preoperative hormonal status, at one month postoperative one patient 
improved (from anterior pituitary insufficiency to only gonadotropin deficiency), one patient 
remained unchanged (anterior pituitary insufficiency), and four patients turned out worse 
(additional ACTH and TSH deficiency resulting in anterior pituitary insufficiency in one; 
additional gonadotropin deficiency in one; panhypopituitarism with newly developed ADH 
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deficiency from anterior pituitary insufficiency in one; anterior pituitary insufficiency from 
normal hormonal status in one). As all patients at least had partial pituitary failure, all 
received hormone replacement accordingly. 
Clinical follow-up at three months postoperative showed improvement of the preoperative 
symptoms (with hormone replacement if necessary) as well normalization of the visual fields 
in all patients. Neuroradiological follow-up at three months postoperative showed total 
resection in four and subtotal resection in two patients with remaining tumor in the cavernous 
sinus (see Fig. 3). Due to persistent elevation of insulin-like growth factor 1 (IGF-1)/GH, the 
patient with acromegaly was reoperated five months later. 
Endocrinological follow-ups between 18 and 32 months postoperative showed further 
improvement in two patients (normal status in one; gonadotropin deficiency in a 60 years old 
female) so that these were independent of hormonal replacement therapy in the longer run. 
Two of the NFA patients (anterior pituitary insufficiency and panhypopituitarism, 
respectively) and the patient with GH/TSH secreting adenoma remained unchanged. One 
patient‘s endocrinological status worsened to an anterior pituitary insufficiency. Therefore, 
compared to the preoperative endocrinological situation, endocrine status in the long-term 
follow-up remained unchanged in four and worsened in two patients. 
Additional neuroradiological follow-ups were performed in five patients between 15 and 46 
months postoperative. These showed stable tumor in two with postoperative minimal residual 
adenoma in the cavernous sinus (questionable in one with normal endocrine status, possibly 
scar formation) and no recurrent tumor in the other patients without residual adenomas. Due 
to persistent elevation of IGF-1 (low GH) and residual adenoma in the cavernous sinus, the 
acromegalic patient was evaluated for stereotactic radiosurgery.
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Discussion 
Giant pituitary adenomas are not unanimously defined in the literature concerning size 
(varying between ≥30 and >40 mm) [1, 7-12, 14, 18, 19]. In this study, PAs ≥40 mm in one 
extension were considered GPAs. Although it is questionable whether the largest diameter 
itself represents the grade of surgical difficulty, this definition seems practicable and is 
accepted in the literature. In our experience, invasion of the cavernous sinus and the middle 
cranial fossa present additional criteria that make radical resection demanding. Especially 
with CS involvement, in ≥60% of cases only subtotal resection is accomplished [1, 8, 9]. 
Attempts to total extirpation result in high complication rates [8, 9]; therefore numerous 
strategies have been proposed to overcome the dilemma between radicality and safety [1, 14, 
15, 20]. 
In 2004, Basso remarked that surgical treatment of non-functioning GPAs presented poor 
results because of the practical impossibility of radical tumor resection with consequent high 
recurrence rates [2]. 
Supplementary guidance by iMRI can improve tumor resection by presenting to the surgeon a 
three-dimensional visualization of the tumor and its residuals not directly accessible to the 
operating microscope or the endoscope, which both display mere surface anatomy. Especially 
in cases where residual adenoma is obscured by structures such as arachnoid pouches, with 
CS invasion, or in situations with pronounced hemorrhage, pathologic tissue is likely to be 
left behind, and iMRI is offering added value. With the support of fully integrated 
neuronavigation, tumor is localized and removed. In addition, the pituitary gland, which may 
often not be distinguished on diagnostic MRIs and in the operative field due to blood, can be 
identified on iMRI scans by following the direction of the stalk, which becomes visible in 
most cases, even after just partial debulking of the adenoma (pituitary stalk sign). We present 
a small sample of six patients with GPAs, which all were operated in a standardized 
endonaso-transsphenoidal way by the senior author (RLB) in the Polestar™ N20 between 
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November 2004 and February 2005. The patients’ characteristics as well as preoperative 
clinical and endocrinological symptoms are comparable with those patients presented in other 
GPA series (Table 1) [1, 8, 9]. MRI scans revealed invasion of the cavernous sinus in all 
patients (Fig. 1). All patients had clinical improvement of preoperative symptoms and 
normalization of visual field deficits. Apart from one patient with postoperative CSF fistula 
(preoperative occlusive hydrocephalus), which required revision, there were no surgical 
complications, although a radical in four or almost radical resection in two patients was 
accomplished. 
Compared to the preoperative situation (Table 2), endocrine status in the long-term follow-up 
(mean, 25 months) remained unchanged in four and worsened in two. Two patients gained 
independence of hormone replacement. 
Long-term neuroradiological follow-up with serial MRI scans (mean, 26 months) showed 
stable tumor in two patients with postoperative CS rest and no residual or recurrent tumor in 
the others (Fig. 3), although in one patient with normal hormonal status, the CS enhancement 
could be related to scar formation (Table 2, Fig. 3). 
Comparison with other series is difficult as only surgical outcome but no endocrinological 
complications or postoperative states (except for permanent DI) have been reported [1, 8, 9]. 
Nonetheless, we can report a much higher total resection rate of 66% (between 27.9% and 
40% according to literature), accompanied by at least as favorable endocrinological outcome 
and symptom control as with conventional pituitary surgery [1, 8, 9].
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Conclusions 
We believe these favorable outcomes are supported by the use of intraoperative imaging, 
which serves as a intraoperative quality control to resection and to preservation of 
surrounding structures beyond that of the operating microscope or endoscope. This 
intraoperative information translates into more radical resections that may lead to fewer 
severe complications, fewer additional procedures (such as transcranial complementary 
operations, hormonal replacement therapy, radiotherapy), and to reducing overall costs of 
therapy of this difficult group of patients. 
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Table 1 Patient characteristics, preoperative symptoms and signs, and adenoma features 
Patient 
number 
Sex Age at 
diagnosis 
Adenoma size and 
type 
Additional 
neuroradiological 
findings 
Preoperative symptoms Preoperative signs Preoperative 
hormonal status 
1 F 60 50*45*34 mm 
Inactive 
Occlusive hydrocephalus Visual disturbance 
fatigue, gait disturbance, 
urinary incontinence, 
memory deficits 
Left hemianopia, 
ataxia 
GT deficiency 
2 M 39 46*44*31 mm 
Active (GH, TSH)
None Visual disturbance, 
sweating, tremor 
Bitemporal 
hemianopia, 
acromegaly, 
intermittent cardiac 
arrhythmias 
GH, TSH 
hypersecretion,  
ACTH, GT 
deficiency 
3 M 36 50*50*50 mm 
Inactive 
None Visual disturbance 
(transient diplopia), 
sexual dysfunction 
Bitemporal 
hemianopia 
ACTH, GT, 
TSH deficiency 
4 M 57 45*22*23 mm 
Inactive 
None Visual disturbance, 
fatigue, sexual 
dysfunction 
Left hemianopia ACTH, GT, 
TSH deficiency 
5 M 51 56*36*39 mm 
Inactive 
None Visual disturbance Left hemianopia Normal 
6 M 34 44*38*27 mm 
Inactive 
Pituitary hemorrhage Visual disturbance 
(diplopia), headache, 
nausea, vomiting 
Bitemporal upper 
quadrantanopia 
ACTH, GT, 
TSH deficiency 
ACTH adrenocorticotropic hormone, GH growth hormone, GT gonadotropin, MRI magnetic resonance imaging, TSH thyroid 
stimulating hormone 
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Table 2 Surgical outcome, complications, and postoperative endocrinological and neuroradiological follow-up 
Patient 
number 
Gross resection and 
immuno-histochemical 
profile 
Postoperative 
complications 
(measures) 
1-month 
postoperative 
endocrinological 
follow-up 
3-month clinical follow-up 3-month 
neuroradiological 
follow-up 
Most recent 
endocrinological 
follow-up 
Most recent 
neuroradiological 
follow-up 
1 Total 
Negative 
 
CSF leak 
(revision), 
transient DI 
(desmopressin) 
GT, ACTH, TSH 
deficiency 
Visual field normalisation, 
preoperative symptoms’, 
signs’ improvement 
No tumor 
residual 
At 23 months: 
GT deficiency, 
ACTH, TSH 
normal 
At 6 months: no 
tumor residual 
2 Subtotal (CS rest), 
reoperation subtotal 
(CS rest) 
GH, TSH 
None IGF-1/GH, TSH 
hypersecretion, 
ACTH, GT 
deficiency 
Visual field normalisation, 
preoperative symptoms’ 
improvement 
Residual 
adenoma (CS) 
At 32 months: 
IGF-1/GH, TSH 
hypersecretion, 
ACTH, GT 
deficiency 
At 25 months: 
stable CS rest 
3 Total 
LH, hCG, ACTH 
None ACTH, GT, TSH 
deficiency 
Visual field, preoperative 
symptoms’ normalisation 
No tumor 
residual 
At 25 months: 
ACTH, GT, TSH 
deficiency 
At 32 months: no 
tumor residual 
4 Total 
LH, hCG 
Permanent DI 
(desmopressin) 
ADH, ACTH, 
GT, TSH 
deficiency 
Visual field, preoperative 
symptoms’ normalisation 
No tumor 
residual 
At 18 months: 
ACTH, GT, TSH 
deficiency 
At 46 months: no 
tumor residual 
5 Subtotal (CS rest)  
HCG 
Transient DI 
(desmopressin), 
transient SIADH 
(fluid restriction)
ACTH, GT, TSH 
deficiency 
Visual field normalisation Residual 
adenoma (CS) 
At 19 months: 
ACTH, GT, TSH 
normal 
At 15 months: 
stable CS rest  
6 Total 
LH 
None GT deficiency visual field, preoperative 
symptoms’ normalization 
No tumor 
residual 
At 31 months: 
ACTH, GT, TSH 
deficiency 
At 29 months: no 
tumor residual 
ADH antidiuretic hormone, ACTH adrenocorticotropic hormone, CS cavernous sinus, CSF cerebrospinal fluid, DI diabetes insipidus, GH growth 
hormone, GT gonadotropin, hCG human chorionic gonadotropin, IGF-1 insulin-like growth factor 1, LH luteinizing hormone, SIADH syndrome of 
inappropriate antidiuretic hormone secretion, TSH thyroid stimulating hormone 
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Fig. 1 Preoperative neuroradiological imaging studies (coronal section above, sagittal section 
below; each pair represents one patient, patient 1 on the left, patient 6 on the right; all are T1-
weighted Gadolinium-enhanced MRI scans, except in patient 5, sagittal section is a CT scan 
with contrast media) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Intraoperative consecutive T1-weighted Gadolinium-enhanced MRI scans (coronal 
section on the left, sagittal reconstructions on the right) illustrating the gradual removal of the 
adenoma in a representative patient (patient number 4) 
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Fig. 3 Postoperative neuroradiological follow-up with MRI scans (T2-weighted coronal 
section above, T1-weighted Gadolinium-enhanced section below; each pair represents one 
patient, patient 1 on the left, patient 6 on the right) 
 
Intraoperative magnetic resonance imaging-guided
transsphenoidal surgery for giant pituitary adenomas
Abstract
Giant pituitary adenomas (GPAs), defined as >/=40 mm in one extension, present a challenging
subgroup of pituitary adenomas in terms of radical tumor removal and complication rates. The potential
impact of intraoperative magnetic resonance imaging (iMRI) is investigated in a consecutive series and
the results compared to the literature. From November 2004 until February 2005, six (five male) patients
were operated for GPAs via an iMRI-guided transsphenoidal approach in the PoleStar N20. Clinical,
endocrinological, and neuroradiological outcomes (at 3 months and yearly postoperative over 4 years)
were assessed. Mean age was 46 years (range, 34-60). All patients presented with preoperative visual
field defects, five with pituitary failure. Five adenomas were clinically nonfunctioning, one was
producing GH and TSH. Preoperative imaging showed invasion of the cavernous sinus in all and
extension to the interventricular foramen in two patients (one with occlusive hydrocephalus). Resection
was total in four and subtotal (small cavernous sinus remnants) in two patients, leading to
transsphenoidal reoperation in one patient. Visual acuity and fields improved in all six patients. The
patient with occlusive hydrocephalus developed a postoperative cerebrospinal fluid leak (subsequently
revised), two patients developed temporary, one permanent central diabetes insipidus, and one of them
transient hyponatremia. Compared to the preoperative situation, endocrine status in the long-term
follow-up (mean, 25 months) remained unchanged in four and worsened in two. Two patients were
considered not to require hormone replacement therapy. IMRI supports transsphenoidal resections of
GPAs because residual adenoma and related risk structures are easily detected and localized
intraoperatively, extending the restricted visual access of the microscope beyond mere surface anatomy
to a three-dimensional view. More radical removal of adenomas in a single surgical session combined
with low complication rates are accomplished. This may add to a favorable clinical and endocrinological
outcome in GPAs.
